AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing pro

Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and

Alkermes (NASDAQ: ALKS - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both heal

LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a

Alkermes is positioned for significant growth through LUMRYZ's potential expansion into idiopathic h

Goldman Sachs analyst Andrea Newkirk reinstates Alkermes (NASDAQ:ALKS) with a Neutral and announc

ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms acr

RBC Capital analyst Leonid Timashev reiterates Alkermes (NASDAQ:ALKS) with a Outperform and maint

Analysts upgraded Fifth Third to Buy and adjusted price targets for Exelon, Alaska Air, Fair Isaac,

Baird analyst Joel Beatty maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price

Alkermes reports positive Phase 1b data for ALKS 7290, showing clinical proof-of-concept for ADHD tr

Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults

Alkermes plc (NASDAQ:ALKS) today announced positive topline results from a phase 1 proof-of-concept

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new indepe

California State Teachers Retirement System increased its stake in Alkermes plc (NASDAQ: ALKS) by 5,

Alkermes plc is upgraded from Hold to Buy, driven by robust revenue growth, pipeline momentum, and s

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting ap

Alkermes (NASDAQ: ALKS - Get Free Report) and C4 Therapeutics (NASDAQ: CCCC - Get Free Report) are b

The executive sold 7,576 shares. The transaction resulted in a 7% reduction in the insider's direct

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

Shares of Alkermes plc (NASDAQ: ALKS - Get Free Report) passed above its 200-day moving average duri

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from th

Bank of America Corp DE decreased its stake in shares of Alkermes plc (NASDAQ: ALKS) by 9.2% in the

Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel

Glenmede Trust Co. NA trimmed its position in shares of Alkermes plc (NASDAQ: ALKS) by 8.4% during t

JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the pric

Baird analyst Joel Beatty maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price

Piper Sandler analyst David Amsellem reiterates Alkermes (NASDAQ:ALKS) with a Overweight and rais

Alkermes (NASDAQ:ALKS) affirms FY2026 sales outlook from $1.730 billion-$1.840 billion to $1.730 bil

Alkermes (NASDAQ:ALKS) reported quarterly sales of $496.009 million which beat the analyst consensus

Stifel analyst Paul Matteis reiterates Alkermes (NASDAQ:ALKS) with a Buy and raises the price tar

Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target

Alkermes reports positive long-term data for alixorexton, showing sustained wakefulness and symptom

Alkermes plc (NASDAQ:ALKS) today announced results from a planned interim analysis of the ongoing lo

On July 6, 2026, Alkermes plc (the "Company") and Amneal Pharmaceuticals LLC ("Amneal&#3

Mizuho analyst Uy Ear maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price tar

Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and raise

Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrad

B of A Securities analyst Jason Gerberry downgrades Alkermes (NASDAQ:ALKS) from Neutral to Underp

Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target

TD Cowen analyst Joseph Thome maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price ta

Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax t

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen

Jim Cramer recommended selling Super Micro Computer Inc. and doesn't recommend Alkermes plc. Hun